Free Radical Research is pleased to announce the publication of a forum issue on protein post-translational modifications in cell signalling and disease.
This issue, guest edited by Francesco Galli and Enrique Cadenas, looks at the role of such modifications in apoptotic signalling and redox sensing, as well as their impact on mitochondrial proteins and functions. Connections between the latter and neurodegenerative diseases, in particular through increased oxidative stress, are discussed. The issue also points to links between protein modifications such as glycation, nitration or succination and metabolic disorders.
For more details, you can download the opening editorial for free and view the table of content page.
Free Radical Research is the official journal of the European and Asian branches of the Society for Free Radical Research. Discounted individual subscriptions are available to the members of these societies.
Wednesday, 15 December 2010
Monday, 13 December 2010
A Special Issue with a Special Offer: Downloads for Donations*
The International Journal of Hyperthermia marked Breast Cancer Awareness Month with a timely Special Issue on the use of hyperthermia as a treatment for this disease. To mark the Special Issue, Informa Healthcare is donating $1 for each download* of the issue’s free-access articles to Susan G. Komen for the Cure®. Susan G. Komen for the Cure® is the world's largest breast cancer charity dedicated to education and research about causes, treatment and the search for a cure.
To date, there have been 3,512 downloads of articles from the Special Issue!
Hyperthermia, as its name suggests, involves raising tumor temperature and the treatment is used to fight disease. Modern advancements in hyperthermia biology have led to refinements for individualized thermochemotherapy approaches to treatments as well as interesting potential for exploiting hyperthermia in conjunction with cancer vaccines. Interest in hyperthermia as a treatment for breast cancer has led to significant advances and research activity which, in turn, has had a significant impact on treatment protocol. Thanks to the volume of research and the impact of published articles, the National Comprehensive Cancer Network (NCCN) now includes hyperthermia in their Breast Cancer Guidelines as a treatment for recurrent cancer.
“The breadth of contributions from the authors in this issue highlights the tremendous progress that has occurred in the role of hyperthermia for the treatment of breast cancer,” says Dr Joan Bull, Co-Guest Editor of the Special Edition.. “This subject has garnered broad national and international interest in this cutting-edge treatment for one of the world’s most high-profile and, unfortunately, prolific diseases.” To view the complete list of articles in the issue, please click here. For more information on the Special Issue, please contact Senior Managing Editor Didi Peng.
*This applies to a full text download of any article from the Special Issue (Volume 26 Issue 7) with a maximum donation of up to $1,500.00.
To date, there have been 3,512 downloads of articles from the Special Issue!
Hyperthermia, as its name suggests, involves raising tumor temperature and the treatment is used to fight disease. Modern advancements in hyperthermia biology have led to refinements for individualized thermochemotherapy approaches to treatments as well as interesting potential for exploiting hyperthermia in conjunction with cancer vaccines. Interest in hyperthermia as a treatment for breast cancer has led to significant advances and research activity which, in turn, has had a significant impact on treatment protocol. Thanks to the volume of research and the impact of published articles, the National Comprehensive Cancer Network (NCCN) now includes hyperthermia in their Breast Cancer Guidelines as a treatment for recurrent cancer.
“The breadth of contributions from the authors in this issue highlights the tremendous progress that has occurred in the role of hyperthermia for the treatment of breast cancer,” says Dr Joan Bull, Co-Guest Editor of the Special Edition.. “This subject has garnered broad national and international interest in this cutting-edge treatment for one of the world’s most high-profile and, unfortunately, prolific diseases.” To view the complete list of articles in the issue, please click here. For more information on the Special Issue, please contact Senior Managing Editor Didi Peng.
*This applies to a full text download of any article from the Special Issue (Volume 26 Issue 7) with a maximum donation of up to $1,500.00.
Wednesday, 8 December 2010
Of abstract importance – new abstract style for 2011
The Expert Opinion journals recognise how important an article's abstract is in drawing in the interested reader. The clearer and more insightful the abstract, the more interest, and potentially more citations, the manuscript will attract. For original research and systematic reviews, structured abstracts are typically required, with guidance on how to prepare these provided by the CONSORT Group. For review articles with free, unstructured abstracts, however, it can be difficult to know how best to present the abstract and what information to include to best represent the full paper. To help authors prepare fitting abstracts and to provide consistency for readers across the Expert Opinion series, in 2011 we are requesting authors include the following in their abstracts for review articles:
- Introduction - describing the significance of the topic and reason for the review
- Areas covered - describing the research discussed and the literature review undertaken
- Expert opinion - summarising the article's 'Expert Opinion' section, a unique feature of all Expert Opinion reviews in which the author goes beyond the conclusion to provide their own personal view of the field
Thursday, 21 October 2010
Pharmaceutical Biology is now indexed on Medline!
October 21, 2010
Informa Healthcare is pleased to announce that Pharmaceutical Biology has been accepted for indexing by Medline, the widely used online bibliographic citation database.
From the Editor-in-Chief:
“As Pharmaceutical Biology approaches its fifth decade of publication, acceptance for indexing by MEDLINE® is a gratifying acknowledgment of our ever-increasing stature in the field. We can now assure our authors of the broadest dissemination of their important contributions describing the pharmacological basis by which natural remedies and drugs function.”
John M. Pezzuto
From the Managing Editor:
“The acceptance of Pharmaceutical Biology for indexing by MEDLINE®, the widely used online bibliographic citation database, is an indication of the scientific merit of its contributions. This milestone is recognition of the importance of this journal.”
Carol Lewandowski
Informa Healthcare is pleased to announce that Pharmaceutical Biology has been accepted for indexing by Medline, the widely used online bibliographic citation database.
From the Editor-in-Chief:
“As Pharmaceutical Biology approaches its fifth decade of publication, acceptance for indexing by MEDLINE® is a gratifying acknowledgment of our ever-increasing stature in the field. We can now assure our authors of the broadest dissemination of their important contributions describing the pharmacological basis by which natural remedies and drugs function.”
John M. Pezzuto
From the Managing Editor:
“The acceptance of Pharmaceutical Biology for indexing by MEDLINE®, the widely used online bibliographic citation database, is an indication of the scientific merit of its contributions. This milestone is recognition of the importance of this journal.”
Carol Lewandowski
Thursday, 14 October 2010
Critical Reviews in Toxicology Vol 40, Special Supplements alert!
October to November 2010
Critical Reviews in Toxicology is pleased to announce that it is producing three special supplements with Volume 40.
Supplement 1 contains 3 open access review articles on the toxicology of Butadiene:
• 1, 3-Butadiene: I. Review of metabolism and the implications to human health risk assessment by C.R. Kirman et al.
• 1, 3-Butadiene: II. Genotoxicity profile by R. J. Albertini .
• 1, 3-Butadiene: III. Assessing carcinogenic modes of action by C.R. Kirman et al.
Supplement 2 reviews the current literature on Benzene and its leukemogenic effects by D. Galbraith et al.
Supplement 3 is an open access comprehensive review paper addressing endocrine disrupting activity by R. J. Witorsch and J. A. Thomas.
Critical Reviews in Toxicology is pleased to announce that it is producing three special supplements with Volume 40.
Supplement 1 contains 3 open access review articles on the toxicology of Butadiene:
• 1, 3-Butadiene: I. Review of metabolism and the implications to human health risk assessment by C.R. Kirman et al.
• 1, 3-Butadiene: II. Genotoxicity profile by R. J. Albertini .
• 1, 3-Butadiene: III. Assessing carcinogenic modes of action by C.R. Kirman et al.
Supplement 2 reviews the current literature on Benzene and its leukemogenic effects by D. Galbraith et al.
Supplement 3 is an open access comprehensive review paper addressing endocrine disrupting activity by R. J. Witorsch and J. A. Thomas.
Monday, 27 September 2010
Issue focus "Antibiotics versus resistant bacteria: recent patents"
In celebration of 20 years of Expert Opinion on Therapeutic Patents, we are delighted to introduce the October issue Guest Edited by Dr Herbert A. Kirst who has supported the journal on its Editorial Board since its early days. For this issue, Dr Kirst has selected a series of reviews discussing results from recent research devoted to finding new antibacterial agents that will improve treatment of infectious diseases, including those caused by strains resistant to current antibiotics.
In his Editorial, Dr Kirst comments that 20 years of calls for action have slowly been heeded since resistance problems first became widely recognized in the late 1980s and early 1990s prompted by the unexpected appearance of resistance to vancomycin.
The reviews in this issue reflect the current state of the competition between evolution of resistance to antimicrobial agents and the development of new agents to overcome such resistance by describing a variety of recent research efforts that have led to new antibacterial agents that are now proceeding through development and regulatory pathways.
We hope you will find the articles insightful and thought provoking.
In his Editorial, Dr Kirst comments that 20 years of calls for action have slowly been heeded since resistance problems first became widely recognized in the late 1980s and early 1990s prompted by the unexpected appearance of resistance to vancomycin.
The reviews in this issue reflect the current state of the competition between evolution of resistance to antimicrobial agents and the development of new agents to overcome such resistance by describing a variety of recent research efforts that have led to new antibacterial agents that are now proceeding through development and regulatory pathways.
We hope you will find the articles insightful and thought provoking.
Friday, 24 September 2010
Special Issue Alert: Transporter-drug interactions and transporter-mediated toxicity in the liver/hepatocyte
Drug Metabolism Reviews
August 2010 Vol. 42, No. 3.
From the Editor-in-Chief:
In the last 20 years, transporters have become the target of many investigations. Their roles in the disposition and development of drugs have been recognized by scientific researchers, drug authorities, and clinicians. The wide substrate specificity or "unspecificity" of these proteins, their presence in many membranes, and their contribution to pharmacokinetics have produced a lot of, as yet, unanswered questions. It has turned out that these proteins may also be the base of drug-drug interactions in human therapy. The investigation of mutations of transporters may contribute to understanding the mechanism of some human diseases. Transporters are also potential targets of new drugs. This special issue edited by Dr. Laszlo Vereczkey, contains seven articles that may be of interest to people dealing with the structure, regulation, activity, and clinical significance of these proteins.
Jack Hinson
August 2010 Vol. 42, No. 3.
From the Editor-in-Chief:
In the last 20 years, transporters have become the target of many investigations. Their roles in the disposition and development of drugs have been recognized by scientific researchers, drug authorities, and clinicians. The wide substrate specificity or "unspecificity" of these proteins, their presence in many membranes, and their contribution to pharmacokinetics have produced a lot of, as yet, unanswered questions. It has turned out that these proteins may also be the base of drug-drug interactions in human therapy. The investigation of mutations of transporters may contribute to understanding the mechanism of some human diseases. Transporters are also potential targets of new drugs. This special issue edited by Dr. Laszlo Vereczkey, contains seven articles that may be of interest to people dealing with the structure, regulation, activity, and clinical significance of these proteins.
Jack Hinson
Subscribe to:
Posts (Atom)
